Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER

NCT06966453 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06966453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06966453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER
Lead sponsor
Pfizer
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 30, 2025
Completion date
January 27, 2030
Enrollment
74 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms